Abstract: Provided are an organic-inorganic hybrid scaffold with surface-immobilized nano-hydroxyapatite, and a method for the fabrication thereof. The scaffold is fabricated by reacting an acid group present on a surface of nano-hydroxyapatite with a primary amine present on a surface of a polymer support in the presence of EDC (1-ethyl-3-dimethylaminopropyl carbodiimide) to immobilize nano-hydroxyapatite onto the surface of the polymer support. The surface of nano-hydroxyapatite is previously grafted with poly(ethylene glycol methacrylate phosphate) (PolyEGMP) having phosphonic acid functionality or with a polymer having carboxylic acid functionality.

Abstract: A bone grafting material composite is provided. The bone grafting material composite includes a demineralized bone matrix (DBM) and a carboxymethyl cellulose (CMC)/glycerol gel carrier. Due to the CMC/glycerol gel carrier, the implantation ability thereof is better than that of the DBM. Therefore, the bone grafting material composite can be easily used, so that a curative effect can be greatly improved. In addition, since the CMC/glycerol gel is used as a carrier, the composite with a mobility maintained is washed out by water after surgery, so that the composite can be fixed on a damaged portion of a bone.

Abstract: Provided are an organic-inorganic hybrid scaffold with surface-immobilized nano-hydroxyapatite, and a method for the fabrication thereof. The scaffold is fabricated by reacting an acid group present on a surface of nano-hydroxyapatite with a primary amine present on a surface of a polymer support in the presence of EDC (1-ethyl-3-dimethylaminopropyl carbodiimide) to immobilize nano-hydroxyapatite onto the surface of the polymer support. The surface of nano-hydroxyapatite is previously grafted with poly(ethylene glycol methacrylate phosphate) (PolyEGMP) having phosphonic acid functionality or with a polymer having carboxylic acid functionality.

Abstract: A bone grafting material composite is provided. The bone grafting material composite includes a demineralized bone matrix (DBM) and a carboxymethyl cellulose (CMC)/glycerol gel carrier. Due to the CMC/glycerol gel carrier, the implantation ability thereof is better than that of the DBM. Therefore, the bone grafting material composite can be easily used, so that a curative effect can be greatly improved. In addition, since the CMC/glycerol gel is used as a carrier, the composite with a mobility maintained is washed out by water after surgery, so that the composite can be fixed on a damaged portion of a bone.

Abstract: A method is provided for producing a virus-inactivated, acellular implant for the human body, featuring the use of TNBP in combination with a detergent selected from among deoxycholate, SDS, Tween 80, Triton X-100, sodium cholate and combinations thereof for removing cells and viruses simultaneously. Also disclosed are an acellular human body implant produced by the method and a wound healing agent comprising the acellular human body implant.

Abstract: The present invention relates to peptides inhibiting elastase and subtilisin activity, which are derived from Guamerin, an elastase-inhibiting protein isolated from a Korean leech, Guameri(Hirudo nipponia). Since the peptides of the invention permit their convenient synthesis and use, it can be applied for the development of elastase- and subtilisin-inhibiting agents. Also, since the dimeric peptides of the invention have strong elastase- and subtilisin-inhibiting activities, they can be more practically applied for the treatment of diseases associated with elastase and subtilisin. Moreover, all of the peptides of the invention can be safely used for human body as a potential drug, since they have relatively lower molecular weights.

Abstract: The present invention provides an elastase-inhibiting protein isolated ("Guamerin") from a Korean leech, Guameri (Hirudo nipponia) and a process for preparing the same. Guamerin is a protein of a molecular weight of 6,110 Da which is composed of 57 amino acid residues, whose active site is composed of 36-methionine and 37-isoleucine, which retains an inhibiting-activity highly specific to elastase, and which shows stability against heat as well as strong acids and alkalies. Guamerin of the present invention can be applied in the treatment of diseases associated with an excess level of elastase, such as rheumatoid arthritis, emphysema, and psoriasis.